Johnson & Johnson Gestione
Criteri Gestione verificati 2/4
Johnson & Johnson Il CEO è Joaquin Duato, nominato in Jan2022, e ha un mandato di 4.5 anni. la retribuzione annua totale è $ 32.76M, composta da 4.9% di stipendio e 95.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.015% delle azioni della società, per un valore di $ 94.73M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.5 anni e 6.1 anni.
Informazioni chiave
Joaquin Duato
Amministratore delegato
US$32.8m
Compenso totale
| Percentuale dello stipendio del CEO | 4.88% |
| Mandato del CEO | 4.5yrs |
| Proprietà del CEO | 0.01% |
| Durata media del management | 4.5yrs |
| Durata media del Consiglio di amministrazione | 6.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jul 17
JNJ: Oncology Focus And New Medicines Will Drive Confidence Through 2026
Analysts raised the Johnson & Johnson fair value estimate to $305 from $265 after a series of price target increases tied to a recent quarterly beat, higher full year guidance, and growing confidence in the company's new medicines and projected revenue trajectory through 2026. Analyst Commentary Recent Street research around Johnson & Johnson has turned more constructive, with a cluster of upgrades and higher price targets following the latest quarterly results and revised guidance.Seeking Alpha • Jul 15
Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street
Summary Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength. JNJ offers stable dividends (>2% yield), high profitability (27.5% operating margin in 2025), and remains a reliable 'buy and hold' within Big Pharma. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 03
JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules
For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.Articolo di analisi • Jun 21
Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...
Aggiornamento narrativa • Jun 19
JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks
Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.Aggiornamento narrativa • Jun 04
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.Aggiornamento narrativa • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Aggiornamento narrativa • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Aggiornamento narrativa • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.Aggiornamento narrativa • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.Nuova narrativa • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Aggiornamento narrativa • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Aggiornamento narrativa • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Aggiornamento narrativa • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.Nuova narrativa • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 28 2026 | n/a | n/a | US$21b |
| Mar 29 2026 | n/a | n/a | US$21b |
| Dec 28 2025 | US$33m | US$2m | US$27b |
| Sep 28 2025 | n/a | n/a | US$25b |
| Jun 29 2025 | n/a | n/a | US$23b |
| Mar 30 2025 | n/a | n/a | US$22b |
| Dec 29 2024 | US$24m | US$2m | US$14b |
| Sep 29 2024 | n/a | n/a | US$15b |
| Jun 30 2024 | n/a | n/a | US$16b |
| Mar 31 2024 | n/a | n/a | US$17b |
| Dec 31 2023 | US$28m | US$2m | US$13b |
| Oct 01 2023 | n/a | n/a | US$12b |
| Jul 02 2023 | n/a | n/a | US$12b |
| Apr 02 2023 | n/a | n/a | US$11b |
| Jan 01 2023 | US$13m | US$1m | US$16b |
| Oct 02 2022 | n/a | n/a | US$18b |
| Jul 03 2022 | n/a | n/a | US$17b |
| Apr 03 2022 | n/a | n/a | US$20b |
| Jan 02 2022 | US$14m | US$1m | US$18b |
| Oct 03 2021 | n/a | n/a | US$18b |
| Jul 04 2021 | n/a | n/a | US$18b |
| Apr 04 2021 | n/a | n/a | US$15b |
| Jan 03 2021 | n/a | n/a | US$15b |
| Sep 27 2020 | n/a | n/a | US$17b |
| Jun 28 2020 | n/a | n/a | US$15b |
| Mar 29 2020 | n/a | n/a | US$17b |
| Dec 29 2019 | US$13m | US$970k | US$15b |
Compensazione vs Mercato: La retribuzione totale di Joaquin ($USD 32.76M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 14.63M ).
Compensazione vs guadagni: La retribuzione di Joaquin è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Joaquin Duato (63 yo)
4.5yrs
Mandato
US$32,758,111
Compensazione
Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 4.5yrs | US$32.76m | 0.015% $ 94.7m | |
| Executive VP & CFO | 8yrs | US$14.41m | 0.0035% $ 22.6m | |
| Executive VP & Worldwide Chairman of Innovative Medicine | 14.5yrs | US$14.03m | 0.0081% $ 51.7m | |
| Executive Vice President of Innovative Medicine and R&D | 3.3yrs | US$12.21m | 0.0010% $ 6.6m | |
| Executive VP & Worldwide Chairman of MedTech | 2.8yrs | US$9.34m | 0.0011% $ 7.0m | |
| Controller & Chief Accounting Officer | 6.6yrs | Nessun dato | 0.0010% $ 6.5m | |
| Executive VP & Chief Information Officer | 6.7yrs | Nessun dato | 0.0011% $ 6.9m | |
| Vice President of Investor Relations | less than a year | Nessun dato | Nessun dato | |
| Chief Compliance Officer | no data | Nessun dato | Nessun dato | |
| Executive VP & Chief Legal Officer | 3.8yrs | Nessun dato | 0.00098% $ 6.3m | |
| Executive VP & Chief Human Resources Officer | no data | Nessun dato | 0.00082% $ 5.3m | |
| Group Chairman of MD&D Business - EMEA | no data | Nessun dato | Nessun dato |
4.5yrs
Durata media
59yo
Età media
Gestione esperta: Il team dirigenziale di JNJ è considerato esperto (durata media dell'incarico 4.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 4.5yrs | US$32.76m | 0.015% $ 94.7m | |
| Director | less than a year | US$59.13k | 0.000080% $ 512.7k | |
| Independent Director | 6.6yrs | US$367.55k | 0.00021% $ 1.3m | |
| Lead Independent Director | 7.3yrs | US$413.00k | 0.00012% $ 769.1k | |
| Independent Director | 3.4yrs | US$344.00k | 0.000010% $ 64.1k | |
| Independent Director | 12.8yrs | US$330.00k | 0% $ 0 | |
| Independent Director | 11.1yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$347.16k | 0.000010% $ 64.1k | |
| Independent Director | 6.6yrs | US$355.00k | 0.000040% $ 256.4k | |
| Director | 1yr | US$62.50k | Nessun dato | |
| Independent Director | 5.6yrs | US$350.00k | 0% $ 0 |
6.1yrs
Durata media
63.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di JNJ sono considerati esperti (durata media dell'incarico 6.1 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/28 14:58 |
| Prezzo dell'azione a fine giornata | 2026/07/28 00:00 |
| Utili | 2026/06/28 |
| Utili annuali | 2025/12/28 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Johnson & Johnson è coperta da 53 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |